Printer Friendly
The Free Library
6,672,335 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

TARO GETS UK MARKETING AUTHORIZATION FOR ETOPAN XL.


Taro Pharmaceutical Industries Ltd., Hawthorne, N.Y. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: TARO) has reported that Taro Pharmaceuticals (UK) Limited (Taro UK), its affiliate in the United Kingdom, has been granted a marketing authorization for Etopan XL Tablets 600 mg, Etodolac etodolac /eto·do·lac/ (e-to-do´lak) a nonsteroidal antiinflammatory drug used as an analgesic and antiinflammatory, especially to treat arthritis.

e·to·do·lac
n.
 (Etopan XL) by the Medicines and Healthcare Products Regulatory Agency The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK government agency which is responsible for ensuring that medicines and medical devices work and are acceptably safe. , the UK equivalent of the U.S. Food and Drug Administration. Etopan XL, a prescription product, is the first approved UK generic alternative to Lodine SR Tablets 600 mg, which is marketed in the UK by Shire Pharmaceuticals. Etopan XL is a non-steroidal anti- inflammatory drug taken for acute or long-term use in rheumatoid arthritis and osteoarthritis. According to industry sources, Lodine SR Tablets have annual sales of approximately US$18 million in the UK. "The introduction of Etopan XL represents a significant addition to our product portfolio in the UK," said Samuel Rubinstein, Senior vice president and general manager of Taro and the head of Taro's European operations.

Tarodent Marketing Authorization in the UK

Taro UK has also been granted a marketing authorization by the Medicines and Healthcare Products Regulatory Agency for Tarodent 0.2% Mouthwash mouthwash /mouth·wash/ (mouth´wosh) a solution for rinsing the mouth.

mouth·wash
n.
A medicated liquid for cleaning the mouth and treating diseased mucous membranes.
, 0.2% w/v chlorhexidine chlorhexidine /chlor·hex·i·dine/ (klor-heks´i-den) an antibacterial effective against a wide variety of gram-negative and gram-positive organisms; used also as the acetate ester, as a preservative for eyedrops, and as the gluconate or  digluconate (Tarodent Mouthwash). Tarodent Mouthwash, an over-the-counter product, is a generic alternative to Corsodyl Mouthwash, which is marketed in the UK by GlaxoSmithKline Consumer Healthcare. Tarodent Mouthwash is used for the treatment and prevention of gingivitis gingivitis (jĭn'jəvī`tĭs), inflammation of the gums. It may be acute, subacute, chronic, or recurrent. The gums usually become red, swollen, and spongy, and bleed easily. , maintenance of oral hygiene and treatment of oral thrush and mouth ulcers.

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

For more information, visit http://www.taro.com or call 914/345-9000, ext. 6208.
COPYRIGHT 2006 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:Dec 1, 2006
Words:282
Previous Article:ASPERVA REPORTS ON PHASE III TRIAL FOR MYASTHENIA GRAVIS.
Next Article:SEMBIOSYS SIGNS PACT FOR CANGENE PLANT-PRODUCED INSULIN.
Topics:



Related Articles
Taro Pharmaceutical Industries strengthens international division with two key appointments.
FDA APPROVES TARO'S ANDA FOR DIFLORASONE DIACETATE CREAM.(Taro Pharmaceuticals Inc.)(Brief Article)(Statistical Data Included)
TARO PHARMACEUTICALS ACQUIRES TIAMOL FOR U.S./CANADA.
Taro Reports Record 2003 Results.
UCB COMPLETES MUTUAL RECOGNITION PROCEDURE FOR EQUASYM XL.
Report to Taro from Independent Counsel Delayed, Expected by October 27, 2006.
View Leading Players in the Global Anticoagulants Market.
Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac.
Taro Receives Extension of Time from Nasdaq Panel for Filing of 2005 Form 20-F.
Taro Files 2005 Form 20-F Following Completion of 2005 Audit.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles